← FDA DRUG APPROVALS

FDA ANDA · ANDA078949

BUDESONIDE

Sponsor: APOTEX

APPLICATION
ANDA078949
TYPE
ANDA
ORIGINAL APPROVAL
2014-05-12
LATEST ACTION
2019-10-29
ROUTE
NASAL
DOSAGE FORM
SPRAY, METERED
MARKETING STATUS
Prescription, Over-the-counter

Products

BUDESONIDEPrescription
BUDESONIDE 0.032MG/INH · SPRAY, METERED · NASAL
BUDESONIDEOver-the-counter
BUDESONIDE 0.032MG/SPRAY · SPRAY, METERED · NASAL

Approval history

2019-10-29Labeling · Supplement 10 · standardAP
2015-11-20Labeling · Supplement 3 · standardAP
2014-05-12OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →